Provider: BehaviorLive — via AVBCC
Take This Course →Including ethics, supervision, and topics like this one. New live CEU every Wednesday.
Join Free →Bringing a breakthrough cancer diagnostic to market requires far more than scientific validation—it demands navigating a complex and evolving ecosystem that includes clinical integration, regulatory strategy, reimbursement models, and patient-centered value. In this timely and forward-looking panel, moderator Bill Behnke, CEO and founder of Cizzle Bio, Inc., will lead a dynamic discussion on the path from biomarker discovery to real-world clinical adoption. Drawing on decades of experience leading healthcare startups and innovation-driven ventures, Behnke will guide a conversation around the key inflection points and hurdles diagnostic companies face on the road to commercialization. Panelists will explore strategies for demonstrating clinical utility and health economic value, aligning with payer and provider expectations in a value-based care landscape, and ensuring that novel technologies remain accessible to diverse patient populations.
| Certification Body | Credits | Type |
|---|---|---|
| BACB | 1 | General |
Dig into the research behind this topic — plain-English summaries written for BCBAs.
127 research articles with practitioner takeaways
Side-by-side comparison with a clinical decision framework
Research-backed educational guide for behavior analysts
Research-backed answers to common clinical questions
All behavior-analytic intervention is individualized. The information on this page is for educational purposes and does not constitute clinical advice. Treatment decisions should be informed by the best available published research, individualized assessment, and obtained with the informed consent of the client or their legal guardian. Behavior analysts are responsible for practicing within the boundaries of their competence and adhering to the BACB Ethics Code for Behavior Analysts.